Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT
- PMID: 28331909
- PMCID: PMC5203689
Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT
Abstract
Background: Insulin resistance and hyperinsulinemia may play a role in pathogenesis of PCOS. One of the common therapeutic methods is using insulin-sensitizing drugs such as metformin and thiazolidinediones.
Objective: The purpose was to determine the effect of metformin and pioglitazone on clinical, hormonal and metabolic parameters in women with PCOS.
Materials and methods: Eighty four women randomly received one of the following for 3 months: metformin (n=28) (500 mg three times a day), pioglitazone (30 mg daily) (n=28) and combination of both metformin and pioglitazone (n=28) (30 mg/day pioglitazone plus 500 mg metformin three times a day). Hormonal profile, fasting serum insulin, body weight, body mass index, menstrual status and waist to hip ratio were evaluated before and after treatment.
Results: Metformin and pioglitazone and combination therapy induced favorable changes in fasting serum insulin, HOMA-IR index, QUICKI, fasting glucose to insulin ratio in women with PCOS. Body weight, BMI, and waist to hip ratio increased significantly after treatment with pioglitazone but the data were similar after administration of metformin or combination therapy. Total testosterone level decreased significantly only after treatment with metformin. After 3 months in patients who received pioglitazone or combination therapy, menstrual cycles became regular in 71.4% and 73.9% respectively. While menstrual improvement happened only in 36.4% of the patients treated with metformin.
Conclusion: These findings suggest that insulin-sensitizing drugs induce beneficial effect in insulin resistance and menstrual cyclicity but only metformin ameliorated hyperandrogenemia in women with PCOS. Treatment with combination of metformin and pioglitazone did not show more benefit than monotherapy with each drug alone.
Keywords: Insulin resistance; Metformin; Pioglitazone; Polycystic ovary syndrome.
Conflict of interest statement
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Figures
Similar articles
-
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.Adv Ther. 2021 Jul;38(7):3842-3856. doi: 10.1007/s12325-021-01789-5. Epub 2021 May 28. Adv Ther. 2021. PMID: 34047916 Clinical Trial.
-
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.J Clin Endocrinol Metab. 2005 Mar;90(3):1360-5. doi: 10.1210/jc.2004-1965. Epub 2004 Dec 14. J Clin Endocrinol Metab. 2005. PMID: 15598674 Clinical Trial.
-
Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.J Endocrinol. 2005 Jan;184(1):233-9. doi: 10.1677/joe.1.05844. J Endocrinol. 2005. PMID: 15642799 Clinical Trial.
-
Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS).Hormones (Athens). 2013 Jul-Sep;12(3):363-78. doi: 10.1007/BF03401302. Hormones (Athens). 2013. PMID: 24121378 Review.
-
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.Cochrane Database Syst Rev. 2003;(3):CD003053. doi: 10.1002/14651858.CD003053. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2009 Jul 08;(3):CD003053. doi: 10.1002/14651858.CD003053.pub2 PMID: 12917943 Updated. Review.
Cited by
-
Metformin Therapy for Acne in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.Am J Clin Dermatol. 2021 Jan;22(1):11-23. doi: 10.1007/s40257-020-00565-5. Am J Clin Dermatol. 2021. PMID: 33048332
-
Comparison of Clinical, Metabolic, Hormonal, and Ultrasound Parameters among the Clomiphene Citrate-Resistant and Clomiphene Citrate-Sensitive Polycystic Ovary Syndrome Women.J Hum Reprod Sci. 2019 Jul-Sep;12(3):216-223. doi: 10.4103/jhrs.JHRS_89_18. J Hum Reprod Sci. 2019. PMID: 31576079 Free PMC article.
-
Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Versus Uptitrated Metformin in Patients with Type 2 Diabetes without Adequate Glycemic Control: A Randomized Clinical Trial.Diabetes Ther. 2024 Nov;15(11):2351-2366. doi: 10.1007/s13300-024-01638-y. Epub 2024 Sep 16. Diabetes Ther. 2024. PMID: 39283411 Free PMC article.
-
Correlation between rs1800871, rs1800872 and rs1800896 Polymorphisms at IL-10 Gene and Lung Cancer Risk.Asian Pac J Cancer Prev. 2024 Jan 1;25(1):287-298. doi: 10.31557/APJCP.2024.25.1.287. Asian Pac J Cancer Prev. 2024. PMID: 38285796 Free PMC article.
-
Association of the CXCL12 rs1801157 Polymorphism with Breast Cancer Risk: A Meta-Analysis.Asian Pac J Cancer Prev. 2024 Mar 1;25(3):767-776. doi: 10.31557/APJCP.2024.25.3.767. Asian Pac J Cancer Prev. 2024. PMID: 38546059 Free PMC article.
References
-
- ESHRE TR, Group A-SPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25. - PubMed
-
- Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis 1. Endocrine Rev. 1997;18:774–800. - PubMed
-
- Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic–hyperinsulaemic clamp. Hum Reprod. 2013:des463. - PubMed
-
- Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab. 1996;81:302–309. - PubMed
-
- Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol. 2004;60:1–17. - PubMed
LinkOut - more resources
Full Text Sources